Measles, Rubella and Congenital Rubella Syndrome (CRS) Country Profile Bermuda

Pan American Health Organization

Introduction

The measles and rubella country profile aims to facilitate the analysis of data compiled in the last five years. This profile was only developed for those countries who officially reported vaccination coverage and case by case surveillance and laboratory data to the Pan American Health Organization (PAHO). There may be minor differences in the country profile if the country has updated data that was not reported to PAHO. The country profile will be automatically updated twice per year: at the end of April (surveillance data) and at the end of September (vaccination coverage data).

General Information

Table 1:	Demogra	aphic	data,	2022.
----------	---------	-------	-------	-------

Demographic group	Population
1 year of age	514
Total population	64,209

Table 2: Last endemic cases by year and disease.

Measles	Rubella	CRS
1990	1990	NA

Table 3: Vaccination schedule.

Vaccine	1st Dose	2nd Dose	MMR2 Year Introduced
MMR	15 mo	4 yr-6 yr	NA

Table 4: Accumulation of susceptibles for measles and rubella.

Year of the	Vaccine	Age	Number	Coverage of the	Number of	Year of
last	used (M,	group	vaccinated	follow-up	susceptibles	next
follow-up	MR,	vacci-	(numera-	$\operatorname{campaign}$	1-4 years of	cam-
$\operatorname{campaign}$	MMR)	nated	$\operatorname{tor})$	(B/C)*100	age	paign
2019	MMR	ND	NA	NA	NA	NA

Epidemiology and Quality of Surveillance




Figure 1: Distribution of suspected MR cases and notification rate at the national level, 2018-2022.

Table 5: Distribution of suspected MR cases and notification rate at the national level, 2018-2022.

	2018	2019	2020	2021	2022
Suspected MR cases	0	0	0	0	0
Suspected MR notification rate per 100,000 population	0	0	0	0	0




Figure 2: Distribution of suspected CRS cases and notification rate at the national level, 2018-2022.

Table 6: Distribution of suspected CRS cases and notification rate at the national level, 2018-2022.

	2018	2019	2020	2021	2022
Suspected CRS cases	0	0	0	0	0
Suspected CRS notification rate per 10,000 live births	0	0	0	0	0

Table 7: Reported cases of measles and rubella by epidemiological year and final classification, 2018-2022.

Classification	2018	2019	2020	2021	2022
Confirmed (Measles)	0	0	0	0	0
Confirmed (Rubella)	0	0	0	0	0

Classification	2018	2019	2020	2021	2022
Pending	0	0	0	0	0
Discarded	0	0	0	0	0
Total	0	0	0	0	0

Figure 3: Performance indicators of measles and rubella surveillance by year, 2018-2022.




Table 8: Municipalities reporting measles and rubella suspected cases by year, 2018-2022.

Year	No. of municipalities reporting suspected cases	Total municipalities in the country	% of municipalities reporting suspected cases
2018	NA	1	0
2019	NA	1	0
2020	0	1	0
2021	NA	1	NA
2022	0	1	0


	No. of municipalities	Total municipalities in	% of municipalities reporting
Year	reporting suspected cases	the country	suspected cases


Laboratory Surveillance

			Criteria for discarding		No.	No. of cases discarded by other differential diagnosis					
Year	No. of suspected cases reported	No. of discarded cases	IgM Negative	No data	Others	Vaccine reaction	Dengue	Parvo virus	Herpes 6	Allergic reaction	Others
2015	3	3	3	0	0	0	0	0	0	0	0

Table 9: Criteria used to discard suspected measles and rubella cases by year, 2015-2015.

Analysis of Vaccination Coverage and Population Cohorts










Figure 5: Coverage of the second dose of measles-mumps-rubella (MMR2) vaccine, number of doses administered, and number of children 4 year(s)-6 year(s) of age, 2018-2022.

Table 10: Vaccination coverage with first and second dose of measles-mumps-rubella (MMR1 and MMR2) vaccines by target population and administered doses, 2018-2022.

	MMR1			MMR2		
Year	Administered doses	Target population	Coverage	Administered doses	Target population	Coverage
2018	510	587	87	463	660	70
2019	587	545	100	591	581	100
2020	522	528	99	431	583	74
2021	495	540	92	384	588	65
2022	421	494	85	335	581	58

Figure 6: Subnational coverage of the first dose of measles-mumps-rubella (MMR1) vaccine and proportion of children aged 1 year, 2021








Figure 7: Proportion of municipalities by MMR1 vaccination coverage ranges, 2018-2022.




Figure 8: Proportion of children living in those municipalities for MMR1 vaccination coverage ranges, 2018-2022.




Figure 9: Proportion of municipalities by MMR2 vaccination coverage ranges, 2018-2022.




Figure 10: Proportion of children living in those municipalities for MMR2 vaccination coverage ranges, 2018-2022.

Table 11: Proportion of municipalities with MMR1 and MMR2 coverage ranges and proportion of children living in those municipalities, 2018-2022.

		MMR1		MMR2	
Year	Coverage range $(\%)$	MMR1	MMR2	MMR1	MMR2
2022	<80	NA	NA	NA	NA
2022	80-89	NA	NA	NA	NA
2022	90-94	NA	NA	NA	NA
2022	95-100	NA	NA	NA	NA
2022	>100	NA	NA	NA	NA
2021	<80	0	100	0	100
2021	80-89	0	0	0	0
2021	90-94	100	0	100	0

2021	95-100	0	0	0	0
2021	>100	0	0	0	0
2019	<80	0	0	0	0
2019	80-89	0	0	0	0
2019	90-94	0	0	0	0
2019	95-100	0	0	0	0
2019	>100	100	100	100	100
2018	<80	0	100	0	100
2018	80-89	100	0	100	0
2018	90-94	0	0	0	0
2018	95-100	0	0	0	0
2018	>100	0	0	0	0

References

Section	Sources
General Information	 [1] United Nations, Department of Economic and Social Affairs, Population Division (2022). World Population Prospects 2022, Online Edition. [2] Country reports through the electronic PAHO-WHO/UNICEF Joint
Epidemiology and Quality of Surveillance	 Reporting Form (eJRF). [3] Integrated Surveillance Information System (ISIS) and country reports to CIM/PAHO. [2] Country reports through the electronic PAHO-WHO/UNICEF Joint
Laboratory Surveillance	Reporting Form (eJRF). [3] Integrated Surveillance Information System (ISIS) and country reports to CIM/PAHO.
Analysis of Vaccination Coverage and Population Cohorts	[2] Country reports through the electronic PAHO-WHO/UNICEF Joint Reporting Form (eJRF).